Recombinant human soluble thrombomodulin for treatment of thrombotic microangiopathy associated with lupus nephritis

Journal of Rheumatology

Volumn 39, Issue 8, 2012, Pages 1766-1767

  Tonooka, Kumiko ^a   Ito, Hiroshi ^a   Shibata, Tomohiko ^a   Ozaki, Shoichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; HAPTOGLOBIN; IMMUNOGLOBULIN G ANTIBODY; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; NIFEDIPINE; PREDNISOLONE; RECOMBINANT THROMBOMODULIN; TELMISARTAN;

ABSENCE OF SIDE EFFECTS; ADULT; ALOPECIA; ANTIGEN ANTIBODY COMPLEX; ARTHRALGIA; CARDIOMEGALY; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; ERYTHEMA; FEMALE; FEVER; FIBRINOGEN BLOOD LEVEL; HEADACHE; HEMATURIA; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKOPENIA; LUNG EDEMA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALIGNANT HYPERTENSION; NEPHROSIS; NORMOCHROMIC NORMOCYTIC ANEMIA; PANCYTOPENIA; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RETICULOCYTOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; FEMALE; HUMANS; LUPUS NEPHRITIS; RECOMBINANT PROTEINS; THROMBOMODULIN; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME;

EID: 84864531765     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111137     Document Type: Letter

References (10)

1. Lansigan F, Isufi I, Tagoe CE. Microangiopathic haemolytic anemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: The role of ADAMTS13. Rheumatology 2011;50:824-9.
2. Letchumanan P, Ng HJ, Lee LH, Thumboo J. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology 2009;48:399-403.
3. Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R. von Willebrand factor cleaving protease (ADAMTs-13) in 123 patients with connective tissue disease. Haematologica 2003;88:914-8.
4. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, et al. ADAMTs13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005;106:1262-7. (Pubitemid 41129589)
5. Nguyen L, Terrell DR, Duval D, Vesely SK, George JN. Complications of plasma exchange in patients treated for thrombotic thorombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion 2009;49:392-4.
6. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin in disseminated intravascular coagulation: Results of phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41. (Pubitemid 44921064)
7. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. J Thromb Haemost 1999;82:718-21.
8. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest 2005;115:1267-74. (Pubitemid 40629045)
9. Ikeguchi H, Maruyama S, Morita Y, Fujita Y, Kato T, Natori Y, et al. Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int 2002;61:490-501. (Pubitemid 34102589)
10. Sharfuddin AA, Sandoval RM, Berg DT, McDougal GE, Campos SB, Phillips CL, et al. Soluble thrombomodulin protects ischemic kidneys. J Am Soc Nephrol 2009;20:524-34.